Pancrelipase Market Research, 2031
The global pancrelipase market was valued at $1.8 billion in 2021, and is projected to reach $2.7 billion by 2031, growing at a CAGR of 4.3% from 2022 to 2031. An exocrine pancreatic insufficiency-related class of drugs known as pancrelipase is used to treat malabsorption and abdominal pain. It is utilized when the pancreas is unable to produce or release sufficient amounts of digestive enzymes into the small intestines to properly digest the food (conditions such as chronic pancreatitis, cystic fibrosis, cancer of the pancreas, post-pancreatectomy, post-gastrointestinal bypass surgery). Pancrelipase, is a combination of lipase, protease, and amylase. Purified porcine pancreatic lipase, amylase, and protease enzymes are used to make pancrelipase.
An increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer is the major factor driving the pancrelipase market growth. People's lifestyles are quickly evolving in the modern era; they are moving toward a new, harmful way of life that includes an unhealthy diet. Pancrelipase is helpful to treat poor digestion caused due to many digestive system-related disorders. Eating a diet low in fiber, not getting enough exercise, traveling or other routine changes, consuming a lot of dairy products, stress, and other lifestyle changes are some of the factors that contribute to digestive difficulties. Thus increasing gastrointestinal diseases due to changing lifestyles people drive market growth.
In addition, pancrelipase is the primary treatment for exocrine pancreatic insufficiency. It is a disorder characterized by a lack of exocrine pancreatic enzymes, which causes maldigestion or an inability to effectively digest food. In this condition, the pancreas is not able to produce enough digestive enzymes. Exocrine pancreatic insufficiency is caused by a variety of disorders, including chronic pancreatitis, cystic fibrosis, pancreatic cancer, post-pancreatectomy, and post-gastrointestinal bypass surgery. The increasing incidence of these diseases propels the market growth. Moreover, in the developing regions, the regulatory authorities have taken key decisions to improve the legislation of pancrelipase drugs, owing to an increase in awareness towards chronic pancreatitis and a rise in use of pancrelipase for the treatment of digestive disorders. Thus developing countries offers lucrative pancrelipase market forecast for growth.
However, manufacturers must file for numerous certifications and tests before releasing their products, which requires a significant financial commitment for the product's acceptance. The employment of expensive and specialized equipment, technologies, and numerous clinical trials all contribute to production costs expected to restrain market growth. Conversely, Emerging economies of Asia-Pacific and LAMEA possess high growth potential for the pancrelipase market opportunity, owing to the rise in purchasing power in these economies is a lucrative opportunity for market growth.
Impact of COVID-19
The COVID-19 pandemic is predicted to have a negative impact on the growth of the global pancrelipase industry. However, during the pandemic the guidelines of maintaining social distancing many patients managed the disease by self-medication or non-medically-approved strategies. During the lockdown manufacturing, logistics and transportation activities were disrupt the supply chain which market growth impedes.
Market Segmentation
The global pancrelipase market is segmented on the basis of application, distribution channel and region. On the basis of application, the market is categorized into chronic pancreatitis, cystic fibrosis and others. By age, it is segmented into children and adult & geriatric. By distribution channel, it is segmented into hospital pharmacies, drug store and retail pharmacies and online pharmacies. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Segment Review
By application, the market is segmented into chronic pancreatitis, cystic fibrosis and others. The chronic pancreatitis segment generated maximum revenue in 2021, and also expected to witness highest CAGR during the forecast period, owing to high incidence of the chronic pancreatitis and upsurge in alcohol consumption.
By age, the pancrelipase market size is segmented into children and adult & geriatric. The adult & geriatric segment generated maximum revenue in 2021, and also expected to witness the highest CAGR during the forecast period, owing to high incidence of the pancreatic cancer in adults and digestive disorders are more common in geriatric population.
Depending on distribution channel, the pancrelipase market size is divided into hospital pharmacies, drug store & retail pharmacies and online pharmacies. The drug store & retail pharmacies segment dominated the pancrelipase market share in 2021, owing to increase in sell of prescription drugs and rise in prevalence of digestive disorders which increases dependence on drug store. The online pharmacies segment is expected to witness highest CAGR during the forecast period owing to convenience and cheaper costs of purchasing prescription drugs electronically.
North America accounted for a majority of the global pancrelipase market share in 2021, and is anticipated to remain dominant during the forecast period. This is attribute surge in incidence of chronic pancretaitis, rise in awareness about usage of pancrelipase, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing rise in incidence pancreatic cancer, development of healthcare infrastructure and increase in investments projects in the region.
The major players profiled in the report are Abbvie Inc, Digestive Care, Inc, Nestlé S.A., Organon Canada Inc., Viatris Inc., Vivus Llc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pancrelipase market analysis from 2021 to 2031 to identify the prevailing pancrelipase industry opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the pancrelipase market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global pancrelipase market trends, key players, market segments, application areas, and market growth strategies.
Pancrelipase Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 2.7 billion |
 Growth Rate | CAGR of 4.3% |
 Forecast period | 2021 - 2031 |
 Report Pages | 157 |
 By Age |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Vivus Llc, Abbvie Inc, Nestlé S.A, Digestive Care, Inc., Organon Canada Inc., Viatris Inc. |
Analyst Review
This section provides opinions of top level CXOs in the global pancrelipase market. According to CXOs, the pancrelipase market has gained momentum in the research, innovation, and development sectors, owing to surge in advancements in pancrelipase by key players. In addition, increase in awareness about importance of digestive health and enzymes leads to surge in demand for pancrelipase which boost the market growth. Emerging economies in Asia-Pacific and LAMEA are expected to present lucrative growth opportunities to key players in the industry, owing to surge in demand for drug discovery.
According to perspectives of CXOs of leading companies, demand for pancrelipase has significantly increase, owing to increase in chronic pancreatitis and pancreatic cancer. However, high cost of treatments associated with drug development may hamper the market growth.
The CXOs further added that North America is expected to remain dominant during the forecast period, owing to factors such as increase in presence of key players. Moreover, Asia-Pacific are expected to offer lucrative opportunities to the market during the forecast period, owing to availability of increase in incidence of the chronic pancreatitis, pancreatic cancer and rise in awareness about the usage of the pancrelipase.
An increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer are the upcoming trends of pancrelipase market growth.
Chronic pancreatitis is the leading application of pancrelipase market.
The global pancrelipase market was valued at $ 1760.41 million in 2021, and is estimated to reach $ 2687.39 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031.
North America is the largest regional market for pancrelipase.
The major players profiled in the pancrelipase market are Abbvie Inc, Digestive Care, Inc, Nestlé S.A., Organon Canada Inc., Viatris Inc., and Vivus Llc.
2021 is the base year of pancrelipase market.
2022 to 2031 is the forecast period of pancrelipase market.
Loading Table Of Content...
